| Not Yet Recruiting | A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum NCT07444684 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 |
| Not Yet Recruiting | Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications NCT07240649 | Jay C. Buckey Jr. | Phase 4 |
| Not Yet Recruiting | A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Py NCT07337564 | Shandong First Medical University | Phase 2 |
| Recruiting | A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum NCT06624670 | Boehringer Ingelheim | Phase 3 |
| Recruiting | Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) NCT06563323 | Oregon Health and Science University | Phase 2 |
| Withdrawn | Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum NCT05984654 | Ohio State University | N/A |
| Withdrawn | Deucravacitinib in PG NCT05821374 | Dartmouth-Hitchcock Medical Center | EARLY_Phase 1 |
| Terminated | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum NCT05964413 | InflaRx GmbH | Phase 3 |
| Completed | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) NCT04901325 | Oregon Health and Science University | Phase 2 |
| Terminated | Spesolimab in Pyoderma Gangrenosum NCT06092216 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Terminated | Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum NCT05343754 | Erasmus Medical Center | Phase 3 |
| Unknown | JAK-STAT Signaling Pathway in Pyoderma Gangrenosum NCT04792957 | Dokuz Eylul University | — |
| Terminated | A Novel Therapeutic Treatment of Pyoderma Gangrenosum NCT05120726 | Louisiana State University Health Sciences Center in New Orleans | Phase 4 |
| Completed | Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma NCT04895566 | SWISS BIOPHARMA MED GmbH | EARLY_Phase 1 |
| Withdrawn | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum NCT04274166 | Wake Forest University Health Sciences | Phase 2 |
| Completed | A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira i NCT04750213 | AbbVie | — |
| Completed | Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum NCT03971643 | InflaRx GmbH | Phase 2 |
| Unknown | Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum NCT03636737 | Assistance Publique Hopitaux De Marseille | — |
| Completed | A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Particip NCT03311464 | AbbVie | Phase 3 |
| Terminated | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum NCT03072953 | Arena Pharmaceuticals | Phase 2 |
| Completed | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum NCT03137160 | Ohio State University | Phase 2 |
| Completed | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangren NCT02733094 | Technical University of Munich | Phase 1 / Phase 2 |
| Terminated | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum NCT02326740 | XOMA (US) LLC | Phase 3 |
| Terminated | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum NCT02318914 | XOMA (US) LLC | Phase 3 |
| Terminated | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum NCT02315417 | XOMA (US) LLC | Phase 3 |
| Completed | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum NCT01965613 | Janssen Research & Development, LLC | Phase 2 |
| Unknown | Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases NCT01952275 | University of Zurich | — |
| Completed | Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum NCT01882504 | XOMA (US) LLC | Phase 2 |
| Completed | Canakinumab for Pyoderma Gangrenosum NCT01302795 | University of Zurich | Phase 2 |
| Withdrawn | Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum NCT00730717 | Wright State University | Phase 2 |
| Completed | Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease NCT00791557 | University Hospitals Cleveland Medical Center | N/A |
| Withdrawn | Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum NCT00690846 | Wake Forest University Health Sciences | Phase 2 |